X-Square Capital’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

X-Square Capital’s Portfolio TCON Stock Details TCON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-887	Closed	-$34K	–	161
2023 Q1	$34K	Sell	887 -12	-1%	-$393	0.02%	148
2022 Q4	$27K	Hold	899	–	–	0.02%	149
2022 Q3	$30K	Hold	899	–	–	0.02%	145
2022 Q2	$36K	Hold	899	–	–	0.02%	150
2022 Q1	$47K	Hold	899	–	–	0.02%	148
2021 Q4	$50K	Hold	899	–	–	0.03%	145
2021 Q3	$70K	Sell	899 -150	-14%	-$12.7K	0.04%	151
2021 Q2	$136K	Hold	1,049	–	–	0.06%	133
2021 Q1	$173K	Buy	+1,049	New	+$202K	0.08%	113
2019 Q4	–	Sell	-360	Closed	-$32K	–	81
2019 Q3	$32K	Sell	360 -36	-9%	-$3.69K	0.02%	75
2019 Q2	$54K	Hold	396	–	–	0.03%	68
2019 Q1	$108K	Hold	396	–	–	0.07%	67
2018 Q4	$50K	Hold	396	–	–	0.04%	70
2018 Q3	$162K	Hold	396	–	–	0.11%	68
2018 Q2	$214K	Hold	396	–	–	0.16%	63
2018 Q1	$183K	Sell	396 -255	-39%	-$139K	0.19%	62
2017 Q4	$436K	Buy	+651	New	+$393K	0.46%	47

Other funds holding TCON

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

X-Square Capital's TCON Position: Q2 2023 in Review

X-Square Capital sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2023, closing a stake of 887 shares — an estimated $34K sold.

X-Square Capital first reported a position in TCON in Q4 2017 and held it in 17 quarters. The position peaked at $436K in Q4 2017. 27 funds tracked by Wall St. Rank hold TCON as of Q2 2023.

X-Square Capital reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
X-Square Capital sold 887 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $34K.
X-Square Capital first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 17 quarters.
X-Square Capital's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $436K in Q4 2017.
27 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on X-Square Capital's 13F filing for Q2 2023, filed 14 Aug 2023.